ALFA Filings
Every announcement, straight from the exchange
Every Glenmark Pharmaceuticals earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements with these filters
Glenmark reported Q1 FY27 consolidated revenue of INR 40,185 million, a 23.1% YoY increase. Performance was driven by India growth (15.5%) and North America recovery (41.1%).
Glenmark delivered robust 23.1% revenue growth for Q1 FY27, driven by strong recovery in North America and steady India outperformance, despite persistent geopolitical cost pressures.
Glenmark reported strong Q1 FY27 results with consolidated revenue of Rs. 40,185 million, representing 23.1% YoY growth. Strategy focuses on core business strengthening and expanding innovation-led platforms like RYALTRIS®.
Glenmark aims to become a US$2bn+ revenue company by FY26, shifting its portfolio mix toward >70% branded products by FY30e through global innovation in Oncology, Respiratory, and Dermatology.
Glenmark reported 15.8% Q4 revenue growth (INR 37,706 Mn) and 27.5% FY26 growth. Strategy focuses on respiratory, oncology innovations, and U.S. injectable ramp-up following a landmark AbbVie licensing deal.
Glenmark delivered strong FY26 growth, hitting gross debt-free status, yet Q4 US margins were squeezed by timing delays and fixed-cost under-absorption.
Glenmark Q4 FY26 consolidated revenue grew 15.8% YoY to ₹37,706m with 20.2% EBITDA margin. Growth driven by landmark AbbVie licensing deal and strong momentum in respiratory franchise.